Partner
with us


Partner with us


We are seeking clinical partners in the US

We are seeking clinical partners in the US




Kyttaro’s primary near-term focus is MSC-Klotho in neurodegenerative disease and longevity. MSC-AAT is prepared for Phase I clinical initiation in the US, building on its Phase I/II regulatory approval in Germany. Kyttaro welcomes partnerships with CDMOs, clinical research organisations, academic institutions, and investors.


We invite interested partners to contact us for more details.

    Academic and Research Partners

    Image

    Kyttaro has submitted an SBIR grant proposal to the NIH for traumatic brain injury in partnership with CHOP. Dr. Todd Kilbaugh, Director of the Resuscitation Science Center at CHOP, serves as co-PI on the grant application for TBI. Dr. Stephan Grupp, Director of the Cancer Immunotherapy Program, is in discussions with Kyttaro regarding MSC-Cyt combination CAR-T cell therapies.

    chop.edu

    Image

    Kyttaro is developing a grant proposal to the NIH in partnership with Johns Hopkins Medicine for ischaemic heart disease using MSC-Klotho. Dr. Gordon Tomaselli, Dean Emeritus of Albert Einstein College of Medicine and Adjunct Professor at Johns Hopkins, leads the group in research discussions with Kyttaro on MSC-Klotho for cardiac arrest.

    jhu.edu

    Image

    Supply agreement for an FDA-approved Master Cell Bank of umbilical cord-derived MSCs already in use for cell transplantation procedures with validated preparative regimens. Provides Kyttaro with a consistent, high-quality cell source for its allogeneic off-the-shelf programmes.

    nybc.org

    Image

    Co-working and shared laboratory space (with ancillary operations in Munich). Kyttaro collaborates with Thermo Fisher’s Advanced Therapies Collaboration Center at BioLabs Philadelphia to develop comprehensive, end-to-end manufacturing workflows for its cell therapy programmes.

    thermofisher.com

    Image

    Industry Partnerships

    Image

    Arnold & Porter is an international law firm with deep expertise in life sciences, regulatory matters, and emerging company representation. They serve as Kyttaro’s US corporate counsel.

    arnoldporter.com

    Image

    Parexel is one of the world’s leading global clinical research organisations (CRO) and our initial partner for clinical trials management. Over the past five years, Parexel has provided regulatory, clinical and technology project services for around 20 regenerative medicine projects and more than 250 cell and gene therapy projects.

    parexel.com

    Image

    HERTIN & Partner is a law firm focused on the protection of inventions, creative activities, trademarks and freedom of action in competitive marketplaces in Germany and beyond. They have served as patent counsel on Kyttaro’s patent portfolio since the inception of the technology.

    hertin.de

    Image

    Alien Technology Transfer USA Inc. offers tailored business support exclusively for pioneering startups and small businesses. With expertise spanning diverse industries, the Alien Technology firm excels in providing strategic counsel that enhances growth, fosters competitive edge, and boosts financial performance.

    alientt.com

    Image

    Builds @ Banc programme – a dedicated service for early-stage startups offering tailored banking solutions and introductions to the Banc’s network of investors and advisors. Kyttaro has been accepted into the Builds @ Banc programme, providing strategic financial and network support.

    bancofcal.com

    Image

    BioLabs for Advanced Therapeutics Philadelphia – The 30,000 sq ft incubator features nine conference rooms, premium event space and a variety of specialized support labs focusing on microbiology, microscopy, process development and more. BioLabs will establish ancillary operations in Munich in 2026. 

    biolabs.io/philly

    Image